Form SD MYOMO, INC.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
Myomo, Inc.
(Exact name of the registrant as specified in its charter)
Delaware |
|
001-38109 |
|
47-0944526 |
|
|
|
|
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
45 Blue Sky Dr., Suite 101, Burlington, Massachusetts |
|
01803 |
|
|
|
(Address of principal executive offices) |
|
(Zip code) |
(617) 996-9058
(Name and telephone number, including area code, of the person to contact in connection with this report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed and provide the period to which the information in this form applies:
☑ |
Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2025. |
☐ |
Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ________. |
Section 1 - Conflict Minerals Disclosures
Item 1.01 – Conflict Minerals Disclosure and Report
A copy of the Company’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and is publicly available at https://ir.myomo.com/corporate-governance/governance-documents
Item 1.02 Exhibit
Exhibit 1.01 – Conflict Minerals Report is attached per Section 1
Section 2 – Resource Extraction Issuer Disclosure
Item 2.01 Resource Extraction Issuer Disclosure and Report
Not applicable.
Section 3 - Exhibits
Item 3.01 – Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
|
MYOMO, INC. |
|
|
Date: May 28, 2026 |
/s/ David Henry |
|
Name: David Henry |
|
Title: Chief Financial Officer |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ballard Power announces results of 2026 Annual General Meeting of Shareholders
- Notice of Multi-Color First Quarter 2026 Financial Results Conference Call
- MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share